CXCR4 and atopic eczema: Here, we rationally designed shortened and highly active analogs of EPI-X4 JM#21, a previous lead compound that showed potent therapeutic effects upon topical application in animal models of CXCR4 associated inflammatory diseases, i.e., atopic dermatitis and allergic asthma20.